STML - Stemline Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue1,041.354654.16335.287
Cost of Revenue---
Gross Profit1,041.354654.16335.287
Operating Expenses
Research Development27,869.92129,458.67621,240.599
Selling General and Administrative12,056.898,828.8438,084.58
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-38,885.457-37,633.359-28,989.892
Income from Continuing Operations
Total Other Income/Expenses Net557.156389.498159.917
Earnings Before Interest and Taxes-38,328.301-37,243.861-28,829.975
Interest Expense---
Income Before Tax-38,328.301-37,243.861-28,829.975
Income Tax Expense-25.296--
Minority Interest---
Net Income From Continuing Ops-38,303.005-37,243.861-28,829.975
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-38,303.005-37,243.861-28,829.975
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-38,303.005-37,243.861-28,829.975